Influence
October 7, 2020

Evaluating the link between medications and dementia: Regenstrief researcher provides consultation

Evaluating the link between medications and dementia: Regenstrief researcher provides consultation

Regenstrief Institute research scientist Noll Campbell, PharmD, M.S., recently contributed to a study that made national headlines and provided more evidence that anticholinergic medications are linked to cognitive decline.

The results from the study, led by researchers at the University of California San Diego School of Medicine, were published in Neurology. The authors concluded that anticholinergics are associated with an increased risk of cognitive decline regardless of the presence of genetic or biomarker risk factors for Alzheimer’s disease.

Dr. Campbell consulted on the study, providing perspective on the data based on similar studies he has been involved with at Regenstrief and Indiana University School of Medicine.  He is listed as an author on the paper.

The past research conducted by Dr. Campbell and his colleagues also provides evidence establishing a link between the common type of medication and cognitive decline. He is now leading a clinical trial to determine if deprescribing anticholinergics improves cognition, which could in turn delay or prevent dementia.

In addition to his role as a research scientist at Regenstrief Institute, Dr. Campbell is an assistant professor of pharmacy practice at the Purdue University College of Pharmacy.

Related News

image of pregnant woman with vaccine acting as protection from COVID virus

National CDC-funded study confirms that mRNA vaccines protect against serious COVID-19 during pregnancy

The first large, real-world study of the effectiveness of mRNA COVID-19 vaccines during pregnancy found these vaccines, especially two

Thomas Imperiale

Journal editorial: Regenstrief researcher calls for tailoring colorectal cancer screening for 45-to-49-year-olds

It’s been a year since national recommendations issued by the American Cancer Society and the U.S. Multi-Society Task Force

Dr. Shaun Grannis on data surveillance of post-COVID conditions

Dr. Shaun Grannis on data surveillance of post-COVID conditions

Regenstrief Vice President for Data and Analytics Shaun Grannis, M.D., M.S., discusses the questions that will be investigated in

Screening tools co-developed by Regenstrief Institute research scientist help clinicians assess and treat vexing symptoms

Screening tools co-developed by Regenstrief Institute research scientist help clinicians assess and treat vexing symptoms

Widely used scales measure pain, depression, anxiety, suicide risk, cancer fatigue and now symptoms associated with a common dental